Cargando…

An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients

SIMPLE SUMMARY: Treatment of patients diagnosed with advanced pulmonary adenocarcinoma depends on the presence of genomic aberrations that are targetable for a specific tyrosine kinase inhibitor. Subsequent treatment lines depend on presence of mutations that are associated with emerging resistance....

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Jiacong, Rybczynska, Anna A., Meng, Pei, Terpstra, Martijn, Saber, Ali, Sietzema, Jantine, Timens, Wim, Schuuring, Ed, Hiltermann, T. Jeroen N., Groen, Harry J. M., van der Wekken, Anthonie J., van den Berg, Anke, Kok, Klaas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650834/ https://www.ncbi.nlm.nih.gov/pubmed/33019710 http://dx.doi.org/10.3390/cancers12102843

Ejemplares similares

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
por: Wei, Jiacong, et al.
Publicado: (2018)

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing
por: Saber, Ali, et al.
Publicado: (2016)

Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer
por: Saber, Ali, et al.
Publicado: (2016)

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
por: Wei, Jiacong, et al.
Publicado: (2021)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

Immune microenvironment composition in non‐small cell lung cancer and its association with survival
por: Tamminga, Menno, et al.
Publicado: (2020)

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare
por: Li, Weiting, et al.
Publicado: (2022)

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression
por: van der Wekken, A. J., et al.
Publicado: (2017)

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
por: Tamminga, Menno, et al.
Publicado: (2019)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor
por: Liu, Bin, et al.
Publicado: (2019)

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors
por: van der Leest, Paul, et al.
Publicado: (2021)

Current Smoking is Associated with Decreased Expression of miR-335-5p in Parenchymal Lung Fibroblasts
por: Ong, Jennie, et al.
Publicado: (2019)

Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch(®) and ISET
por: Tamminga, Menno, et al.
Publicado: (2020)

Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients
por: Meng, Pei, et al.
Publicado: (2019)

A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
por: Koopman, Bart, et al.
Publicado: (2021)

Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome
por: Kerner, Gerald S. M. A., et al.
Publicado: (2013)

Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort
por: Koopman, Bart, et al.
Publicado: (2022)

Differential miRNA Expression Profiles in Cumulus and Mural Granulosa Cells from Human Pre-ovulatory Follicles
por: Andrei, Daniela, et al.
Publicado: (2019)

Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients
por: Tamminga, Menno, et al.
Publicado: (2020)

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
por: Boonstra, Pieter A., et al.
Publicado: (2020)

Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
por: Nijland, Marcel, et al.
Publicado: (2018)

CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma
por: Veldman, Johanna, et al.
Publicado: (2022)

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2023)

Marked TGF-β-regulated miRNA expression changes in both COPD and control lung fibroblasts
por: Ong, J., et al.
Publicado: (2019)

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer
por: Donker, H. C., et al.
Publicado: (2023)

Involvement of MicroRNAs in the Aging-Related Decline of CD28 Expression by Human T Cells
por: Teteloshvili, Nato, et al.
Publicado: (2018)

Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2018)

Non‐small‐cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy
por: Koopman, Bart, et al.
Publicado: (2021)

Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients
por: van der Leest, Paul, et al.
Publicado: (2023)

Microarray amplification bias: loss of 30% differentially expressed genes due to long probe – poly(A)-tail distances
por: Boelens, Mirjam C, et al.
Publicado: (2007)

The miR-26b-5p/KPNA2 Axis Is an Important Regulator of Burkitt Lymphoma Cell Growth
por: Niu, Fubiao, et al.
Publicado: (2020)

Mining for viral fragments in methylation enriched sequencing data
por: Mensaert, Klaas, et al.
Publicado: (2015)

Can ACE2 expression explain SARS‐CoV‐2 infection of the respiratory epithelia in COVID‐19?
por: Nawijn, Martijn C, et al.
Publicado: (2020)

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
por: Meertens, Marinda, et al.
Publicado: (2023)

Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients
por: Koele, Simon E., et al.
Publicado: (2021)

MiR-378a-3p Is Critical for Burkitt Lymphoma Cell Growth
por: Niu, Fubiao, et al.
Publicado: (2020)

The potential of combined mutation sequencing of plasma circulating cell‐free DNA and matched white blood cells for treatment response prediction
por: van der Leest, Paul, et al.
Publicado: (2020)

Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non–Small-Cell Lung Cancer in the Netherlands
por: Wolff, Henri B., et al.
Publicado: (2022)

SETD2: an epigenetic modifier with tumor suppressor functionality
por: Li, Jun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_punrq6dc45q6cl3s158agc0ci2